Kenneth L. Londoner, MBA
Founder, Chief Executive Officer, Chairman, and Director
Mr. Londoner is a capital markets and capital architecture expert and a senior life science executive. Having started his career as a research analyst for J. & W. Seligman & Co., Inc., a leading institutional money management firm in New York City, NY, he quickly found himself at the forefront of the biotech industry in the early 1990s, leading him to manage $3.5 billion in mutual and pension funds and international assets.
His passion for medical innovation led him to co-found, govern and bring to the public market a number of life science companies, including BioSig Technologies, Inc. [Nasdaq:BSGM]. Working in close collaboration with key opinion leaders in electrophysiology, BioSig aims to improve the outcomes of cardiac ablations for the treatment of arrhythmias through novel technological solutions developed by the company, and further apply its core competency in advanced biomedical signal processing and analysis to other areas of medicine.
His prior experience in recognizing the early potential of biotech led Londoner to form the Alliance for Advancing Bioelectronic Medicine, an independent non-profit network of professionals dedicated to innovation at the intersection of healthcare and technology. The Alliance aims to increase awareness of bioelectronic medicine and build a platform for collaboration among stakeholders. Over the last decade, Londoner formed top level relationships with a number of medical centers of excellence such as Mayo Clinic, NYU Langone Hospital and UCLA, as well as other stakeholders, including investment communities, intellectual property experts and supply chain partners.
Chief Financial Officer
Mr. Chaussy has served as Chief Financial Officer of BioSig Technologies, Inc., since May of 2011, making him one of the Company’s most veteran executives. He brings an impressive array of professional experiences, detailed protocols, and an adept understanding of the financial operations of public companies.
Mr. Chaussy has an extensive entrepreneurial growth and development background from working for Penske Truck Leasing Co., L.P., a Penske Corporation subsidiary, where his improvements of management and reporting tools allowed the Company to double in size. Since 2005, Mr. Chaussy has been the sole proprietor of Anna & Co., Inc., a consulting company that offers services to small publicly traded companies. Anna & Co., Inc. provides general financial and accounting services, emphasizing SEC reporting and compliance, to companies that lack sufficient resources to hire full-time employees to offer such services. From 2001 to 2005, Mr. Chaussy provided services as both a Chief Financial Officer and a consultant to small publicly traded companies. Before 2001, Mr. Chaussy served as the chief financial officer for a large private distribution and wholesaling Company, where he gained international experience.
Executive Vice President
Natasha Drapeau has been with BioSig Technologies, Inc. since May of 2017 and is primarily responsible for leading Company operations. Based in Geneva, Switzerland, Ms. Drapeau is BioSig’s primary executive for future European operations. She works closely with the Board of Directors and strategic partners, including medical centers of excellence and IP advisors. Ms. Drapeau serves as President at NeuroClear, Inc., Executive Vice President at BioSig Technologies, Inc., and is a founding member of the Alliance for Advancing Bioelectronic Medicine.
Ms. Drapeau brings over 18 years of international business development experience, including more than nine years at IG Group Plc, a leading British FTSE 250 financial services company. While working for IG, she was responsible for the Group’s global business development, including a worldwide rebranding and business support to 16 international offices in Europe, South Africa, Singapore, and Australia.
Mrs. Drapeau holds two MSc degrees with honors in Management and German from Samara Academy of Economics, as well as a Business, International Relations, and Political Economy degree from The London School of Economics. Mrs. Drapeau is a member of the Institute of Directors in the United Kingdom.
Dr. Barry Keenan, Ph.D., MBA, PMP
Vice President, Engineering
Dr. Keenan has been with BioSig Technologies, Inc. since March of 2019, and brings to the Company over 20 years of industry experience. He is a subject matter expert in R&D, product development and commercialization, neuromodulation, deep brain stimulation, sensing, imaging, and cardiac pacing. A biomedical engineer by training, Dr. Keenan spent over nine years at Medtronic Diabetes. He was responsible for all algorithm development and successfully developed the MiniMedTM ParadigmTM VeoTM and iProTM2 Professional Continuous Glucose Monitoring (CGM). One of Dr. Keenan's career highlights was the development and successful clinical evaluation of the MiniMedTM 670G, the world's first artificial pancreas. This invention became one of the top revenue-generating products for Medtronic. The research was featured in Time magazine's 25 Best Inventions of 2013 and 2016 and named one of the Best Medical Technologies of 2016.
Since 2014, Dr. Keenan has been actively involved with the Alfred Mann Foundation for Scientific Research as CTO, Vice President of Research & Development, and Board member. During Dr. Keenan's engagement with the Foundation, he managed an R&D department of over 40 scientists and engineers consisting of software, firmware, electrical, mechanical, and ASIC groups developing innovative medical devices, implanted neuromodulation, and sensing systems.
Dr. Keenan is a winner of several awards and is a Medtronic Technical Fellow. His team at Medtronic won Technical Contributors of the Year for their work in the Artificial Pancreas, which also achieved 'Best of What's New' in Popular Science's health category. Dr. Keenan is an inventor of 39 patents and authored over 30 scientific manuscripts and book chapters.
Dr. Keenan has a B.A. in Electrical and Electronics Engineering from University of Ulster, an MBA from Queens University, a Ph.D. in Biomedical/Medical Engineering from University of Ulster, a Doctoral Research degree from University of Michigan, and an MBA from Cornell University.
Director of Human Resources
A seasoned executive, Ms. Castrodad brings a wealth of experience in leading organizational development in start-ups and Fortune 500 companies within the life sciences sector. Most recently, Ms. Castrodad led the HR department at TissueTech, Inc., a Miami, FL-based biotech leader in regenerative amniotic tissue-based products, where she was responsible for transformation and automation of the company’s HR practices, talent planning, and team building. Prior to TissueTech, Inc., Ms. Castrodad spent six years at HeartWare, Inc., a heart failure medtech company acquired by Medtronic [NYSE:MDT] in 2016 for $1.1 billion. By optimizing the internal talent acquisition function and aligning business practices, Ms. Castrodad helped grow the organization from approx. 80 to 500+ staff which achieved approx. $250 million in revenues before the acquisition. Earlier in her career, Ms. Castrodad spent 16 years at Schering-Plough Corp, a pharmaceutical company acquired in 2009 for $41.1 billion by Merck & Co. [NYSE:MRK]. Ms. Castrodad holds a Master’s Degree in Public Administration and a Bachelor’s Degree in Social Sciences – Human Welfare from the University of Puerto Rico and a Labor Relations Certificate from the University of Michigan.
Vice President, Investor Relations
Mr. Ballou brings to BioSig over 25 years of experience in capital markets, including institutional equity sales and research analysis. Most recently, Mr. Ballou served as Managing Director, Head of Institutional Equity Sales at Janney Montgomery Scott LLC., a role in which he oversaw key accounts, including large multi-manager hedge funds, mutual funds and dedicated sector funds. Prior to that role Mr. Ballou managed selected key account coverage at RBC Capital Markets, including Millennium Partners, Soros Fund Management, SIR Capital, Columbia Threadneedle, Two Sigma Investments and Times Square Capital Management. During the course of his career Mr. Ballou analyzed various private and public companies in healthcare, media and retail sectors. Mr. Ballou graduated from Hampden-Sydney College, Virginia, with a Bachelor of Arts in English.
Vice President, Sales
Mr. Kowalski brings to the Company over 30 years of experience in medical device sales, including over 20 years at Biosense Webster, a Johnson & Johnson company. Most recently, he served as Northeast Area Director, a role, in which he was responsible for leading six high-performing cardiac electrophysiology catheter and equipment market sales teams, consisting of 140 sales and clinical support employees. Mr. Kowalski helped drive $175M of disposables and system sales and has consistently exceeded area sales objectives. Having led U.S. strategic planning teams in his previous roles, Mr. Kowalski brings to BioSig proven track record in identifying key business growth opportunities within the cardiac electrophysiology market.
Mr. Kowalski is a holder of numerous Biosense Webster leadership awards, including a record 18-year Founders Club Award, and several “Area and Region of the Year” awards.
Vice President, Administration
As Vice President of Administration, Ms. Mikolaitis' role encompasses a wide range of duties that began with co-writing the business plan to now co-writing marketing materials and SEC filings. She supports many of the departments of the Company including shareholder/investor/public relations, accounting/finance, legal, marketing, human resources, and research and development. Ms. Mikolaitis is also President of Miko Consulting Group, Inc., a firm that provides marketing research and administrative support to life science companies.
Vice President, Clinical Affairs
Mrs. Stephenson brings to BioSig over 20 years of cardiac device technology experience having served in various clinical, sales, and marketing roles at Medtronic, Boston Scientific, and Guidant Corporation. Most recently, Mrs. Stephenson served as Director of Medical Education at Medtronic, a role in which she developed and delivered over 10 national peer-to-peer education programs annually and was responsible for numerous other supplemental educational resources for EP fellows. This work included collaboration with internationally recognized physician leaders. Other highlights of Mrs. Stephenson’s career with Medtronic included supervising the contracting and honoraria processes, serving as the Medical Education Liaison to Latin America, and participating in the Global Innovation Fellowship Program.
Earlier in her career, Mrs. Stephenson was the Regional Sales Manager with Boston Scientific in Central New Jersey for three years. During this time Mrs. Stephenson was responsible for driving meaningful sales revenues. Prior to this, she served as a Sales Representative and Field Clinical Representative with Guidant Corporation for 7 years.
A critical care nurse by training, Mrs. Stephenson holds a BSN degree from Northwestern State University and MBA from The Darden School of Business at University of Virginia. Mrs. Stephenson received numerous awards, including the President’s Club Award, Regional Sales Manager of the Year (New York Area), a Patent Award, and the Faculty Award.
Senior Director of Marketing
Mr. Chaudoir brings to BioSig over 20 years of medical technology experience, including over 15 years in electrophysiology. Most recently, Mr. Chaudoir served as WW Senior Global Strategic Marketing Director at DePuy Synthes (a Johnson & Johnson company), a role, during which he led strategic competitive assessments in the sector of spinal enabling technologies and established a multi-generation technology roadmap and execution plan. Prior to it, Mr. Chaudoir spent 17 years at Biosense Webster in the U.S., France and Belgium. During this time, he progressed from the field clinical support roles to Atrial Fibrillation Specialist to Regional Business Director and successfully led the company’s operations in Northern and Southern California. One of the highlights of Mr. Chaudoir’s career include a successful global launch of CARTOÒ3 Navigation System. Mr. Chaudoir’s contributions to this product launch include development of innovative commercial marketing programs to enable customer acceptance for the US, Japanese and Chinese electrophysiology markets. Mr. Chaudoir is a holder of a Marketing Mastery Award (FUSE JNJ MD&D Global Surgery). He graduated from Pole Academique de Bruxelles (Belgium) school with the BSc degree in Biomedical Electronics Engineering and University of Sussex in the UK with a MSc degree in Digital Electronics and Parallel Processing Systems. Mr. Chaudoir completed The Berkeley Executive Leadership Program and is bilingual in French and English.
Senior Director of Strategic Planning
Ms. Patwardhan brings to BioSig over 18 years of program management and product development experience with several Fortune 500 companies in the medical technology, pharma and healthcare verticals. A biomedical engineer by training, Ms. Patwardhan’s core competencies span manufacturing and vendor management, systems engineering, cross-functional team leadership and process improvements. Most recently, Ms. Patwardhan was in a technical program management role at Verily Life Sciences, LLC, an Alphabet, Inc. company, a role, in which she led hardware development for a class III therapy technology program as well as supply-chain and vendor management. Prior to that, Ms. Patwardhan was employed by Boston Scientific - Neuromodulation, where she was responsible for delivering a range of technology and product development programs, including commercially launched products in the Spinal Cord Stimulation portfolio as well as a connected health eco system. Earlier in her career Ms. Patwardhan was with Medtronic Diabetes, where she led product development efforts for class II therapy, diagnostic and combination products. Her work involved the delivery of engineering solutions from cross-functional teams comprising human factors, marketing, industrial design, hardware and software design and third-party vendors. Ms. Patwardhan holds a Master of Science in Biomedical Engineering from the University of Southern California Los Angeles and Bachelor of Engineering, Chemical Engineering from University of Pune, India.
Director of Regulatory Affairs / Quality Assurance
With over 20 years of senior management experience in Fortune 500 companies, European notified bodies, and start-ups in the US, Europe, and Asia, Mr. Riechert is an expert in regulatory affairs. He has specialized experience in design controls and technical documentation and leads BioSig’s medical device compliance and quality assurance team.
Over the course of his impressive career, Mr. Riechert has achieved a host of medical device approvals, including 510(k) clearances, European CE markings, and other international clearances for a range of devices, including RF ablation generators, ablation catheters, and guidewires. Mr. Riechert served as a General Manager for TUV Rheinland for six years, where he managed three offices, working in Germany, the US, Japan, and Taiwan. His professional experience also includes serving as a Principal RA Consultant at Oriel Stat A Matrix, Director of Regulatory Affairs for Zeltiq Aesthetics, Inc., and Senior Manager for International Regulatory Affairs for Acclarent Inc (a J&J Company). Additionally, Mr. Riechert received professional training as an Electrical Energy Systems Technician at Dynamit Nobel, Troisdorf, Germany.
Mr. Riechert holds an MBA from the University of Phoenix and a BSEE from the University of Siegen, Germany.
Sasha Gentling, CFA
Director of Business Development and Investments
Prior to joining the Company, Ms. Gentling served as Investment Officer at Mayo Clinic, a role, in which she managed key components of Mayo Clinic’s investment portfolio, overseeing external manager relationships in absolute return core credit hedge fund strategies, fixed income, and real estate private equity, as well as conducting comprehensive due diligence on potential new investments in both public and private markets. Prior to that role Ms. Gentling managed investor communications and marketing activities at Connecticut based Discerene Group, during which time AUM increased by over $700 million. During the course of her career Ms. Gentling conducted extensive research for emerging value-oriented hedge funds and generated investment recommendations by building and maintaining earnings, valuation models and financial projections. Ms. Gentling holds an MBA in Finance and Management from Columbia Business School and a BA in English and Music from Middlebury College.